Q&A: Sanofi’s R&D head reflects on his first year, a post-Dupixent future, and finding an identity

Almost a year ago, Sanofi made history for the wrong reasons.

Last October, CEO Paul Hudson announced strategic changes including boosting R&D spending and pulling …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

More Kids Getting Their Hands on Nonprescription Weight-Loss Products

Nearly one in 10 adolescents across the globe have used a nonprescription weight-loss product, according to a systematic review and meta-analysis. Across 90 studies, 8.9%

January 11, 2024

Is bigger better? McKinsey predicts the return of large medtech mergers

Dive Brief: McKinsey analysts think big medtech deals could be back on the agenda, arguing mergers make sense at a time when companies are under

September 22, 2023

Telix’s $397M convertible bond offering; Scynexis records a $10M milestone

Plus, news about Windtree Therapeutics, MEI Pharma and ViiV: Telix raises $397M in convertible bond offering: The radiopharma biotech plans to use the funds to

July 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.